

**Amendment**

The following listing of the claims replaces all prior versions and listings of the claims in the application.

**Listing of the Claims:**

1-37. (Cancelled)

38. (Currently amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen fragment comprising an amino acid sequence from any of SEQ ID NOs: 179-356 or fragments thereof encoded by a nucleic acid molecule fragment of SEQ ID NO:110 and comprising amino acids 4-37, 40-46, 52-57, 199-205, 222-229, 236-244, 250-267, 269-282, 27-197, 86-109, and/or 104-127 of SEQ ID NO:288.

39-46. (Cancelled)

47. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, further defined as comprising at least two different hyperimmune serum-reactive antigens and/or fragments.

48. (Cancelled)

49. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, further comprising an immunostimulatory substance.

50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

51. (Previously Presented) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.

52. (Previously Presented) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.

53. (Currently amended) The pharmaceutical composition of claim ~~[[45]]~~38, further defined as wherein the composition is a vaccine.

54. (Currently amended) The pharmaceutical composition of claim 53, ~~further defined as~~  
wherein the vaccine is a vaccine for treatment and/or prevention of *H. pylori* infection.
55. (Withdrawn) A method of vaccinating a subject comprising:  
obtaining a pharmaceutical composition of claim 45; and  
administering the pharmaceutical composition to a subject;  
wherein the subject is vaccinated.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the method is a method of treating and/or preventing *H. pylori* infection in the subject.
58. (Withdrawn) The method of claim 55, wherein the hyperimmune serum-reactive antigen or fragment is directed against *H. pylori*.
59. (Withdrawn) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens or fragments thereof.
60. (Withdrawn) The method of claim 59, wherein the at least two different hyperimmune serum-reactive antigens or fragments thereof are both directed against *H. pylori*.